Taro Postpones Shareholders Meetings on Proposed Merger With Sun Pharma

  Taro Postpones Shareholders Meetings on Proposed Merger With Sun Pharma

Business Wire

HAWTHORNE, N.Y. -- November 14, 2012

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro”) announced today that
it has postponed its extraordinary general meeting of shareholders and the
class meeting of holders of ordinary shares, originally scheduled for December
6, 2012, to consider the proposed merger of Taro with a subsidiary of Sun
Pharmaceutical Industries, Ltd. (“Sun Pharma,” Reuters: SUN.BO, Bloomberg:
SUNP IN, NSE: SUNPHARMA, BSE: 524715). Taro will set a new record date for the
rescheduled meetings and will mail a supplemental notice together with proxy
materials to its shareholders.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based
pharmaceutical company, dedicated to meeting the needs of its customers
through the discovery, development, manufacturing and marketing of the highest
quality healthcare products. For further information on Taro Pharmaceutical
Industries Ltd., please visit the Company’s website at www.taro.com.

SAFE HARBOR STATEMENT

Certain statements in this press release are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These
statements include, but are not limited to, statements that do not describe
historical facts and statements that refer or relate to events or
circumstances Taro “estimates,” “believes,” or “expects” to happen or similar
language. The forward-looking statements in this press release are based on
Taro’s current expectations and are made only as of the date of this press
release and involve certain risks and uncertainties that could cause actual
results to differ materially from future results that may be expressed or
implied by such forward-looking statements. Unless required by law, Taro
undertakes no obligations to update, change or revise any forward-looking
statement, whether as a result of new information, additional or subsequent
developments or otherwise.

Contact:

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer
William.Coote@taro.com
 
Press spacebar to pause and continue. Press esc to stop.